Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
A phase 3 trial of Acalabrutinib, Rituximab and Chlorambucil in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia is a phase 3 interventional study registered as NCT04075292 by AstraZeneca, with 155 participants enrolled, started 2020-01-20 and due to reach its primary completion in 2024-01-03. Interventions recorded: Acalabrutinib, Rituximab and Chlorambucil. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialA Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Shares Acalabrutinib, Rituximab, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Acalabrutinib, Rituximab, AstraZeneca and the tag pipeline.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialA Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Shares Chlorambucil, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.